Análise da estratégia regulatória de priorização da análise de registro de medicamentos na Anvisa: evidências empíricas e desafios regulatórios
Vigilância Sanitária em Debate · 23.06.2026 · 1-15
DOI: 10.22239/2317-269x.02537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vigilância Sanitária em Debate, online erschienen am 23.06.2026. Verfasst von Henrique Mansano Rosa Oliveira und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This article analyzes the prioritization strategy for reviewing drug registration applications implemented by the Agência Nacional de Vigilância Sanitária through RDC 204/2017 and 205/2017, focusing on the regulatory strategy and management of the backlog of applications.
Objective
To evaluate the prioritization strategy for the review of drug registration applications at Anvisa regarding its effects on the timeliness of application review and the reduction of the regulatory backlog, which is understood as the stock of pending application.
Method
This is a descriptive, quantitative, and longitudinal study based on the indicator “quarterly evolution of prioritized drug registration applications,” composed of entries, outputs, and accumulated backlog. Data was obtained from the Regulatory Impact Analysis, the Business Intelligence database of the General Office of Medicines, and the application queue. The period analyzed comprised January 2018 to December 2024. Data were organized into time series and analyzed using descriptive statistics.
Results
The proposed indicator showed an increase in the number of prioritized applications from 2019 onwards and institutional efforts to expand review capacity from 2021. However, the accumulated backlog showed an upward trend over most of the period, peaking in 2024, indicating limitations of the strategy in reducing waiting time.
Conclusions
The prioritization strategy is relevant but insufficient when applied in isolation to reduce the backlog and improve timeliness at Anvisa. The findings indicate the need to articulate it within a broader regulatory strategy, based on risk management, data use, and mechanisms such as reliance and agile regulation, to improve performance and the predictability of the regulatory process.
Zitieren
APA
Oliveira, H. M. R., & Neto, J. D. A. (2026). Análise da estratégia regulatória de priorização da análise de registro de medicamentos na Anvisa: evidências empíricas e desafios regulatórios. Vigilância Sanitária em Debate, 1-15. https://doi.org/10.22239/2317-269x.02537
Vancouver
Oliveira HMR, Neto JDA. Análise da estratégia regulatória de priorização da análise de registro de medicamentos na Anvisa: evidências empíricas e desafios regulatórios. Vigilância Sanitária em Debate. 2026:1-15. doi:10.22239/2317-269x.02537
BibTeX
@article{Oliveira2026,
author = {Oliveira, Henrique Mansano Rosa and Neto, João de Almeida},
title = {Análise da estratégia regulatória de priorização da análise de registro de medicamentos na Anvisa: evidências empíricas e desafios regulatórios},
journal = {Vigilância Sanitária em Debate},
year = {2026},
pages = {1--15},
doi = {10.22239/2317-269x.02537}
}
EUVIMED